NeoPhore Limited
NeoPhore is a biotech company focused on discovering and developing small molecule immuno-oncology therapeutics targeting the DNA mismatch repair (MMR) pathway. Their approach aims to stimulate immunity directly at cancer’s core by creating neoantigens, which can improve outcomes for patients who do not benefit from current immunotherapies. NeoPhore collaborates with academic and commercial organizations, including their scientific founders from the University of Turin, and operates a mainly virtual drug discovery & development model with a dedicated laboratory in South London.
Industries
Nr. of Employees
small (1-50)
NeoPhore Limited
Cambridge, Cambridgeshire, United Kingdom, Europe
Products
DNA Mismatch Repair Inhibitors
Small molecule drugs targeting the DNA mismatch repair pathway to induce neoantigen expression and increase immunogenicity in solid tumors.
Continuous Neoantigen Creation
A process that generates new antigens from DNA mutations in tumor cells, enhancing the immune system's ability to recognize and attack cancer cells.
PMS2 Modulators
Compounds developed to modulate the PMS2 protein, transforming immune 'cold' tumors to 'hot' and increasing sensitivity to immune checkpoint inhibitors.
MLH1 Modulators
Compounds targeting the MLH1 protein, which plays a key role in the DNA mismatch repair process and is often non-functional in certain cancers.
Next Generation Targets
Research and development efforts focused on identifying and targeting additional proteins within the DNA mismatch repair pathway for cancer treatment.
DNA Mismatch Repair Inhibitors
Small molecule drugs targeting the DNA mismatch repair pathway to induce neoantigen expression and increase immunogenicity in solid tumors.
Continuous Neoantigen Creation
A process that generates new antigens from DNA mutations in tumor cells, enhancing the immune system's ability to recognize and attack cancer cells.
PMS2 Modulators
Compounds developed to modulate the PMS2 protein, transforming immune 'cold' tumors to 'hot' and increasing sensitivity to immune checkpoint inhibitors.
MLH1 Modulators
Compounds targeting the MLH1 protein, which plays a key role in the DNA mismatch repair process and is often non-functional in certain cancers.
Next Generation Targets
Research and development efforts focused on identifying and targeting additional proteins within the DNA mismatch repair pathway for cancer treatment.
Services
Discovery and development of small-molecule immuno-oncology therapeutics
End-to-end discovery activities focused on identifying and progressing small molecules that modulate mismatch repair biology to increase tumour neoantigen generation and enable combination with immunotherapies.
Preclinical research and translational support
Preclinical assay development, in vitro and in vivo studies, biomarker development and validation, and translational planning to support IND/CTA/EMA filings and early clinical studies.
Bioinformatics and NGS analysis services
Design, execution and oversight of NGS analysis pipelines (WES/WGS), mutational signature analysis, neoantigen prediction, MSI assessment, and genomic data presentation for research and translational applications.
Discovery and development of small-molecule immuno-oncology therapeutics
End-to-end discovery activities focused on identifying and progressing small molecules that modulate mismatch repair biology to increase tumour neoantigen generation and enable combination with immunotherapies.
Preclinical research and translational support
Preclinical assay development, in vitro and in vivo studies, biomarker development and validation, and translational planning to support IND/CTA/EMA filings and early clinical studies.
Bioinformatics and NGS analysis services
Design, execution and oversight of NGS analysis pipelines (WES/WGS), mutational signature analysis, neoantigen prediction, MSI assessment, and genomic data presentation for research and translational applications.
Expertise Areas
- Immuno‑oncology translational research
- Small molecule oncology drug discovery
- DNA damage response and mismatch repair biology
- Preclinical pharmacology and PK/PD
Key Technologies
- Small-molecule medicinal chemistry (MMR-targeted)
- Whole-exome sequencing (WES)
- Low-pass whole-genome sequencing (WGS)
- Tumour mutational burden (TMB) analysis